The Roche test that found an EZH2 mutation in follicular lymphoma to select tazemetostat. Tazemetostat has since been withdrawn, and the FDA records the test's own approval as withdrawn on 6 July 2026.
Roche Molecular Systems' cobas EZH2 Mutation Test was approved on 18 June 2020 (PMA P200014) to identify people with follicular lymphoma whose tumour carries an EZH2 mutation, for treatment with tazemetostat (Tazverik). The FDA's PMA page for the test gives a withdrawal date of 6 July 2026, and openFDA's copy of the same database gives the original approval the decision code APWD, which its field definitions define as withdrawal after approval. The FDA companion diagnostic list, last updated on 3 November 2026, still printed the test. Tazemetostat itself was withdrawn in 2026 (see its page).
Real-time allele-specific PCR for the EZH2 single-nucleotide mutations Y646N, Y646F, Y646X (Y646H, Y646S or Y646C), A682G and A692V in DNA from formalin-fixed, paraffin-embedded follicular lymphoma tissue. Connects to EZH2.
| Where | Who pays | Help with the cost | |
|---|---|---|---|
| 🇺🇸 United States | Approved 2020 | - | - |
Approval is the regulator's decision for any cancer indication, with the year of the first; it is not a promise that a hospital stocks the drug or that your indication is covered. Not recorded for European Union, United Kingdom, Japan, China, Australia, India: a gap in our research, not a refusal. Compare products across regions.
| Region | Year | Indication |
|---|---|---|
| US | 2020 | Companion diagnostic for tazemetostat in EZH2-mutant follicular lymphoma · Approval withdrawn on 6 July 2026 (FDA PMA page, withdrawal date; openFDA decision code APWD) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"cobas EZH2 Mutation Test" OR ABSTRACT:"cobas EZH2 Mutation Test") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about cobas EZH2 Mutation Test, not a curated reading list.
Shares Companion diagnostic, Pathologic complete response (pCR), Companion diagnostics, Roche / Genentech and the tag test.
Shares Companion diagnostic, Pathologic complete response (pCR), Companion diagnostics, Roche / Genentech and the tag test.
Shares Companion diagnostic, Companion diagnostics, Roche / Genentech and the tag test.
Shares Companion diagnostic, Companion diagnostics, Roche / Genentech and the tag test.
Shares Companion diagnostic, Companion diagnostics, Roche / Genentech and the tag test.
Shares Companion diagnostic, Companion diagnostics, Roche / Genentech and the tag test.
Shares Companion diagnostic, Pathologic complete response (pCR), Companion diagnostics and the tag test.
Shares Companion diagnostic, Pathologic complete response (pCR), Companion diagnostics and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/